Biomolecule-Conjugated PROTAC Technology Development
Biomolecule-Conjugated PROTAC Technology Development
* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Biomolecule-conjugated PROTAC technology integrates the catalytic degradation capability of PROTACs with the targeting, recognition, delivery, or binding advantages of biomolecules such as antibodies, peptides, aptamers, oligonucleotides, and protein ligands. BOC Sciences provides customized biomolecule-conjugated PROTAC technology development services, supporting clients from feasibility assessment and conjugate design to synthesis, analytical characterization, degradation validation, and iterative optimization. Our platform helps pharmaceutical and biotechnology researchers address key challenges in selective delivery, intracellular release, linker chemistry, target engagement, and degradation activity, enabling more precise exploration of next-generation targeted protein degradation strategies.
Services
BOC Sciences' Biomolecule-Conjugated PROTAC Development Services
Biomolecule-conjugated PROTAC projects require coordinated expertise in degrader design, bioconjugation chemistry, biomolecule engineering, analytical characterization, and degradation biology. BOC Sciences offers modular and end-to-end support to help clients evaluate whether a biomolecule-guided degradation strategy is technically feasible and how it can be advanced efficiently.
Feasibility Assessment and Strategy Design
We evaluate the client's target protein, cell-type selectivity requirement, available targeting biomolecule, PROTAC payload, intracellular trafficking route, and expected degradation mechanism. This early assessment helps define whether an antibody-, peptide-, aptamer-, or oligonucleotide-conjugated format is most suitable for the project.
Target biology and degradation rationale analysis
Biomolecule format selection based on project goals
Internalization, localization, and release-pathway assessment
Degrader payload feasibility and physicochemical risk evaluation
Integrated development roadmap and risk-control strategy
PROTAC Payload Design and Optimization
A biomolecule-conjugated PROTAC requires a degrader payload that can maintain target engagement, E3 ligase recruitment, and degradation activity after release or spatial presentation. We support payload selection, modification-position analysis, and optimization of warhead, E3 ligand, and linker compatibility through PROTAC design services.
Warhead and E3 ligand pairing strategy
Payload modification site evaluation
CRBN-, VHL-, IAP-, or MDM2-oriented design options
Payload potency, selectivity, and developability optimization
Focused analog design for conjugation-compatible degraders
Biomolecule Selection and Engineering Support
We help clients select or optimize biomolecules that can provide cell recognition, target binding, delivery enhancement, or conditional activation. Depending on the project objective, we support antibody fragments, peptides, aptamers, oligonucleotides, protein ligands, and other biomolecular recognition elements.
Antibody, peptide, aptamer, and oligonucleotide format comparison
Binding motif and conjugation-site feasibility analysis
Biomolecule stability and modification compatibility assessment
The linker in a biomolecule-conjugated PROTAC must balance conjugation stability, release behavior, steric accessibility, solubility, and payload activity. BOC Sciences provides linker design and optimization services to support both cleavable and non-cleavable conjugate architectures.
Cleavable and non-cleavable linker design
Spacer length, flexibility, and hydrophilicity optimization
Site-specific and controlled conjugation strategy
Release-trigger selection based on intracellular environment
Conjugation chemistry compatibility evaluation
Biomolecule-PROTAC Conjugate Synthesis
We provide chemistry and bioconjugation support for the preparation of biomolecule-PROTAC conjugates, including payload synthesis, linker installation, biomolecule modification, conjugation reaction development, purification, and sample delivery for downstream evaluation.
PROTAC payload synthesis and derivatization
Biomolecule functionalization and activation
Conjugation reaction condition screening
Purification and formulation support for research samples
Preparation of small-scale exploratory conjugate panels
Analytical Characterization and Quality Evaluation
Biomolecule-conjugated PROTACs often show higher structural complexity than conventional bifunctional degraders. We support analytical characterization to help clients understand conjugation efficiency, molecular integrity, purity, aggregation tendency, payload loading, and stability under research-use conditions.
Molecular weight and conjugation confirmation
Purity, aggregation, and size-distribution analysis
Payload-to-biomolecule ratio evaluation
Buffer compatibility and short-term stability assessment
Comparative analysis of conjugate batches and analogs
Cellular Uptake and Trafficking Evaluation
For antibody-, peptide-, aptamer-, and oligonucleotide-conjugated PROTACs, cellular uptake and intracellular distribution can directly determine degradation performance. We support receptor binding, internalization, endosomal escape, release behavior, and subcellular localization studies.
Cell binding and internalization analysis
Receptor-positive and receptor-negative cell model comparison
Intracellular trafficking and localization evaluation
Payload release and exposure assessment
Delivery strategy optimization through PROTAC delivery support
Degradation Activity and Functional Validation
We validate whether the conjugate induces target protein degradation in relevant cellular systems and whether degradation translates into expected pathway or phenotypic effects. Our services include PROTAC in vitro evaluation, cell-based degradation assays, and mechanism-focused validation.
Target protein degradation analysis by Western blot or quantitative assays
DC50, Dmax, and time-course evaluation
Cell-selectivity comparison using biomarker-positive and negative models
Proteasome-dependency and mechanism confirmation
Functional pathway and downstream biomarker analysis
Are These Challenges Slowing Your Biomolecule-Conjugated PROTAC Project?
Unclear choice between antibody-, peptide-, aptamer-, and oligonucleotide-conjugated formats
Loss of PROTAC degradation activity after linker installation or biomolecule conjugation
Difficulty balancing conjugate stability with intracellular payload release
Poor internalization, limited endosomal escape, or insufficient intracellular payload exposure
Complex analytical characterization of heterogeneous conjugates
Inconsistent degradation results across receptor-positive and receptor-negative cell models
Tell Us Your Challenge
Contact us to discuss your biomolecule-conjugated PROTAC design, synthesis, and validation needs.
Different biomolecules solve different problems. Some provide cell-type recognition, some improve payload delivery, and others enable new target engagement or localization strategies. BOC Sciences helps clients select the most suitable conjugate format according to the target protein, disease-relevant cell model, degradation goal, and available biomolecule resources.
Antibody-PROTAC Conjugates
Antibody-PROTAC conjugates are designed to use antibody-mediated recognition and internalization to deliver PROTAC payloads into selected antigen-expressing cells. BOC Sciences supports feasibility assessment, payload modification, linker design, and conjugation strategy development through PROTAC-antibody conjugates design.
Suitable for projects requiring cell-surface antigen-guided selectivity
Supports exploration of intracellular degradation after antibody-mediated uptake
Requires careful optimization of payload release and conjugate homogeneity
Peptide-Conjugated PROTACs
Peptide-conjugated PROTACs can use cell-penetrating peptides, targeting peptides, or peptide ligands to improve delivery or recognition. We help clients evaluate peptide sequence design, conjugation position, stability, and effects on degradation performance, with support for peptide-based PROTAC technology development.
Useful for delivery enhancement and receptor-guided targeting studies
Can be designed with cleavable or stable linker strategies
Requires optimization of peptide stability, charge, and cellular uptake
Aptamer-PROTAC Conjugates
Aptamers offer sequence-defined recognition and can be engineered for selective binding to cell-surface or soluble targets. We support aptamer-PROTAC conjugate concept design, linker placement, conjugation chemistry, and cellular uptake/degradation validation, drawing on experience in aptamer-drug conjugates design.
Suitable for projects requiring nucleic-acid-based targeting modules
Supports exploration of receptor-mediated delivery and selective exposure
Requires attention to nuclease stability and intracellular trafficking
Oligonucleotide- and RNA-PROTAC Conjugates
Oligonucleotide- and RNA-linked PROTAC concepts can be used to explore hybrid delivery, targeting, or localization strategies. BOC Sciences supports payload attachment, spacer design, delivery feasibility, and degradation validation for projects involving oligonucleotide-based PROTACs development or RNA-PROTACs technology development.
Supports exploratory projects involving nucleic-acid-guided delivery or recognition
Requires careful control of charge, stability, and cellular accessibility
Benefits from coordinated oligonucleotide chemistry and PROTAC biology
Challenge Solving
Our Solutions for Biomolecule-Conjugated PROTAC Development Challenges
The success of a biomolecule-conjugated PROTAC depends on more than simply attaching a degrader to a biomolecule. The conjugate must reach the correct cells, remain stable during delivery, release or present the payload in a productive form, recruit the appropriate E3 ligase, and generate measurable target degradation. BOC Sciences applies a problem-solving workflow to identify and optimize the critical variables for each project.
Solution for Format Selection
We compare biomolecule formats according to target antigen availability, internalization potential, intracellular localization, conjugation feasibility, and expected degradation readout. This helps clients avoid selecting a conjugate architecture that is attractive conceptually but unsuitable for the biological system.
Solution for Linker and Release Optimization
We design linker systems that balance plasma- or media-facing stability with intracellular accessibility. Depending on the project, we evaluate enzyme-cleavable, reduction-sensitive, acid-sensitive, self-immolative, PEGylated, or sterically tuned spacer designs, supported by linker binding site selection and design.
Solution for Payload Activity Retention
We assess whether linker installation disrupts warhead binding, E3 ligand orientation, ternary complex formation, or physicochemical properties. When activity is reduced, we redesign the modification site, linker length, and E3 ligase ligand pairing, and validate productive ternary-complex behavior through PROTAC ternary complex assay support.
Solution for Cellular Delivery and Degradation Validation
We combine receptor-positive/negative cell models, uptake analysis, degradation assays, proteasome-dependency confirmation, and functional readouts to determine whether limited activity is caused by poor delivery, insufficient payload release, weak target engagement, or inadequate E3 ligase recruitment.
Build More Selective PROTAC Strategies with Biomolecule-Guided Conjugation
BOC Sciences provides integrated biomolecule-conjugated PROTAC technology development support, combining degrader chemistry, biomolecule modification, conjugation design, cellular delivery evaluation, and degradation biology to help clients move from concept to validated research candidates.
Biomolecule-Conjugated PROTAC Solutions for Diverse R&D Needs
Pharmaceutical Discovery Teams
Discovery teams exploring targets with systemic degradation concerns need strategies that improve cell selectivity and delivery precision. We help evaluate whether biomolecule-guided PROTAC delivery can improve project differentiation compared with conventional small-molecule degraders.
Biotechnology Companies
Biotech teams often need rapid proof-of-concept data to support pipeline prioritization. We provide focused design-synthesis-validation cycles that help clarify whether a biomolecule-conjugated PROTAC format can generate selective degradation in relevant cellular systems.
Academic and Translational Research Groups
Academic groups may have strong target biology or biomolecule discovery experience but require support in degrader payload design and conjugate validation. We help translate biological concepts into testable conjugate molecules and robust degradation experiments.
CROs and Technology Platforms
CROs and platform companies can use our modular support to expand capacity in PROTAC payload chemistry, bioconjugation, linker optimization, analytical characterization, and degradation activity testing without building every capability internally.
Biomolecule-Conjugated PROTAC Development Workflow
01
Requirement Collection and Project Definition
Collect target protein information, available ligands or degraders, biomolecule sequence or structure, intended cell model, degradation goal, and sample delivery requirements.
Assess cell binding, internalization, target protein degradation, dose response, degradation kinetics, and selectivity across relevant cell models.
08
Optimization and Data Reporting
Refine the conjugate design based on activity and analytical results, then deliver research samples, experimental data, and clear recommendations for the next design cycle.
Evaluation
Assays and Characterization Methods for Biomolecule-Conjugated PROTACs
Because biomolecule-conjugated PROTACs combine large biomolecular components with small-molecule degraders, their evaluation must capture both conjugate integrity and biological function. BOC Sciences designs fit-for-purpose assay packages according to conjugate type, target biology, and project stage.
Conjugate Identity and Integrity
Molecular weight confirmation and conjugation verification
Purity and size-distribution analysis
Aggregation and fragmentation assessment
Payload loading or conjugation ratio estimation
Stability and Release Behavior
Buffer and media stability comparison
Linker cleavage or payload release analysis
Short-term storage and handling-condition assessment
Exploratory stability comparison across linker designs
Cellular Delivery and Target Engagement
Cell binding and internalization analysis
Receptor-positive versus receptor-negative cell comparison
Intracellular localization and trafficking evaluation
Target engagement and pathway-relevant biomarker readouts
Degradation and Functional Activity
Target protein degradation by Western blot, ELISA, or quantitative cellular assays
Proteasome-dependency and E3 ligase-dependency confirmation
Functional cellular response and selectivity analysis
Advantages
Advantages of Biomolecule-Conjugated PROTAC Technology
Improved Cell-Type Targeting
Biomolecules such as antibodies, peptides, and aptamers can provide recognition modules that guide PROTAC payloads toward selected cell populations or receptors.
Expanded Delivery Options
Conjugation strategies can help explore delivery routes that are difficult to achieve with conventional small-molecule PROTACs alone.
Flexible Modular Design
PROTAC payloads, linkers, and biomolecule carriers can be independently optimized to match different targets, cell models, and research objectives.
Enhanced Mechanistic Exploration
Biomolecule-guided degraders allow researchers to study how delivery, internalization, localization, and degradation are connected in complex biological systems.
Applications
Research Applications of Biomolecule-Conjugated PROTACs
Cell-Selective Target Degradation
Degradation in antigen-positive or receptor-positive cell models
Comparison of degradation selectivity across matched cell lines
Exploration of cell-surface marker-guided PROTAC delivery
Support for oncology and immunology target research
Intracellular Delivery Enhancement
Peptide-, aptamer-, or oligonucleotide-assisted payload transport
Evaluation of uptake, trafficking, and endosomal escape
Optimization of linker chemistry for intracellular release
Support for targets requiring improved cellular exposure
Targeted Protein Degradation Tool Development
Generation of research probes for pathway and target validation
Degradation-based investigation of protein function
Comparative evaluation against inhibitor-only approaches
Design of negative controls and non-releasing conjugate controls
Next-Generation TPD Platform Exploration
Biomolecule-assisted degrader platform construction
Exploratory comparison with lysosomal or extracellular degradation approaches
Data generation for platform differentiation and internal decision-making
Case
Client Success Stories: Biomolecule-Conjugated PROTAC Technology Development
Project Background
A biotechnology client had developed a potent BRD4 PROTAC payload in a conventional small-molecule format but observed similar degradation activity in both marker-positive and marker-negative cell models. The team wanted to explore whether an antibody-guided conjugate could improve cell-selective degradation in HER2-expressing cells while maintaining payload activity after intracellular release.
Our Support
BOC Sciences first evaluated the payload structure and identified a linker-tolerant modification position that was unlikely to disrupt BRD4 warhead binding or E3 ligase recruitment. We then designed three linker families with different spacer lengths and release properties and prepared a focused panel of antibody-PROTAC conjugates using controlled conjugation conditions. After purification and analytical characterization, the conjugates were tested in HER2-high and HER2-low breast cancer cell models. The best-performing design showed clear receptor-associated uptake, measurable BRD4 degradation in the HER2-high model, and substantially reduced activity in the HER2-low comparison model. Based on degradation intensity, conjugate integrity, and cellular uptake data, we recommended one cleavable linker design for the client's next optimization round.
Project Outcome
The client received a data-supported conjugate design strategy, characterized research samples, and comparative degradation results that clarified how antibody format, linker release, and payload structure affected selective degradation. This enabled the client to prioritize a more focused antibody-PROTAC optimization path rather than continuing broad empirical conjugation attempts.
Project Background
A pharmaceutical research group was developing a kinase-targeted PROTAC series but encountered weak cellular degradation despite acceptable biochemical binding data. The client suspected that limited cellular entry and high molecular polarity were restricting intracellular payload exposure. They requested a peptide-conjugated PROTAC strategy to evaluate whether a delivery peptide could improve cellular uptake without eliminating degradation activity.
Our Support
We reviewed the client's PROTAC structure, kinase target profile, and available cell-based assay system, then designed a peptide-conjugated PROTAC panel using two cell-penetrating peptide motifs, three spacer lengths, and both stable and cleavable linker designs. The conjugates were prepared and characterized for purity, size distribution, and short-term stability. In cellular testing, several conjugates showed improved uptake compared with the unconjugated degrader. However, only the cleavable mid-length spacer retained strong degradation activity, indicating that intracellular payload release was more important than uptake alone. This lead conjugate achieved a clear dose-dependent reduction of the target protein in the client's selected cell model, while non-cleavable controls showed weaker degradation despite visible cellular internalization.
Project Outcome
The project identified the key limitation of the original PROTAC series and delivered a practical optimization direction: improve intracellular exposure through peptide-assisted delivery while preserving release of an active degrader payload. The client used the results to refine linker selection and focus subsequent analog synthesis on release-competent peptide-PROTAC designs.
Why Us
Why Choose BOC Sciences for Biomolecule-Conjugated PROTAC Development?
Integrated PROTAC and Bioconjugation Expertise
We combine degrader design, linker chemistry, biomolecule modification, conjugation development, and degradation biology within one coordinated workflow.
Multiple Biomolecule Formats
We support antibody-, peptide-, aptamer-, oligonucleotide-, RNA-, and protein-ligand-guided conjugate strategies for different research goals.
Problem-Oriented Linker Optimization
Our linker design considers conjugation site, stability, intracellular release, spacer length, steric exposure, and retention of degrader activity.
Decision-Driven Biological Validation
We design assays that distinguish delivery failure, release failure, target engagement loss, and E3 recruitment limitations to guide the next optimization cycle.
Flexible Modular or End-to-End Support
Clients can request individual service modules or integrated support from concept design through conjugate synthesis and degradation validation.
Clear Reporting and Scientific Communication
We provide structured data interpretation and practical recommendations to help clients make confident decisions about conjugate redesign and project advancement.
Biomolecule-conjugated PROTACs are designed to combine the protein degradation mechanism of PROTACs with the recognition, delivery, or targeting advantages of biomolecules such as antibodies, peptides, aptamers, or oligonucleotides. For drug discovery researchers, this strategy is especially valuable when conventional small-molecule PROTACs face challenges related to cell selectivity, intracellular delivery, solubility, or tissue-relevant exposure. By selecting a suitable biomolecule carrier and linker system, researchers can explore more directed degradation strategies while maintaining target protein engagement and E3 ligase recruitment.
How does conjugation improve PROTAC selectivity?
Conjugation can improve PROTAC selectivity by using a biomolecule to guide the degrader toward specific cell types, surface receptors, or biological contexts before the active PROTAC is released or positioned for intracellular action. For example, antibody- or aptamer-guided systems may help reduce unwanted activity in non-target cells by relying on receptor-mediated binding and internalization. Selectivity still depends on multiple factors, including antigen expression, internalization efficiency, linker cleavage behavior, payload release, target engagement, and degradation pathway compatibility.
Which biomolecules can be used in PROTAC conjugates?
Common biomolecule formats for PROTAC conjugation include antibodies, antibody fragments, peptides, aptamers, oligonucleotides, and other protein- or nucleic-acid-based carriers. Each format has different advantages: antibodies offer strong cell-surface recognition, peptides can support modular and compact designs, aptamers provide sequence-programmable binding potential, and oligonucleotide-based systems may support specialized delivery or recognition strategies. BOC Sciences helps clients evaluate biomolecule compatibility, conjugation chemistry, linker architecture, and degrader release requirements according to the target biology and project goals.
What challenges affect biomolecule-PROTAC development?
Key challenges include maintaining biomolecule binding after conjugation, preserving PROTAC degradation potency, achieving efficient cellular uptake, controlling linker stability and release, and balancing molecular size with delivery performance. Researchers also need to consider drug-to-biomolecule ratio, conjugation site selection, aggregation risk, degradation assay design, and whether the released or conjugated degrader can access the intended intracellular target. A successful program usually requires coordinated optimization of the biomolecule, linker, PROTAC payload, and biological evaluation workflow.
How can BOC Sciences support this development?
BOC Sciences supports biomolecule-conjugated PROTAC technology development through integrated services covering target and biomolecule assessment, PROTAC payload design, E3 ligase ligand selection, linker and conjugation strategy development, synthesis, conjugate preparation, and in vitro degradation evaluation. Our team can help compare different conjugation sites, linker chemistries, release mechanisms, and biomolecule formats to identify designs with stronger degradation activity and project suitability. This enables clients to move from concept validation to optimized conjugate candidates with clearer experimental evidence.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Improved Cell-Type Targeting
